However, per the previous analysis of CASPIAN [16], and in contrast to findings in advanced NSCLC [13], evaluation of outcomes in patient subgroups defined according to a tTMB cut-off of 10 mut/Mb did not show a difference in OS. Here, TMEM200B is linked to non-small cell lung carcinoma.